PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III

Starting this Thread to demonstrate the upcoming year of Trials ahead for Pharmaust.

The title says it all.

Human Covid Trial , Multiple Clinics in discussion with PAA adding to the pool of positive data gained from WEHI from 2 Independent Trials, Biolabs 360 and the Leiden University in Holland.
MPL in the Lab demonstrated that MPL can reduce the Viral Load by 50% in the first 24 hours and 95% over the coming 72 hours,,
This Trial should be short and swift and from the reputation of the above institutes the results will be replicable.
Leading to a safe robust Treatment that should reduce Hospitalisation times and assist those that have contracted Covid and possibly the entire SARs-1 and SARs-2 family, this would be a breakthrough Treatment.


MND Motor Neuron Disease , Fully Funded by MND Australia



K9 Phase III , specialist negotiator brought on board to secure a Phase III K9 Lymphoma Trial Partner or early Commercial Deal.
The Company already has solid confirmation of the benefits of MPL and now wish to trial with a companion drug to increase the benefits to K9's , this data will be utilised for the upcoming Human Trials.



Human Oncology , PAA intend to replicate the Positive Results from the 2016 Human Cancer Trial negating any of the previous minor adverse effects. This will be a "Take at Home" cancer treatment with no harmful adverse side effects negating the use of aggressive Chemotherapy.



HVTL-1 Based Virus the cousin of HIV and a precursor to Leukemia ,WEHI identified Positive effect of MPL.





The company are awaiting the delivery of refined and micronised MPL , "Pharmapantel" the Tablets/Pill has been designed to be very small to reduce patient burden and easier to swallow.



2022 is Pharmausts year in the Spotlight , NZT